Know What's Happening in Business

Science Closes $230M Series C Funding

Science, the Alameda‑based neural engineering firm, closed a $230 million Series C round, raising its total capital to roughly $490 million since 2021. The financing will accelerate commercialization of its brain‑computer interface retinal implant, PRIMA, and expand research, manufacturing, and bio‑hybrid neural platforms. PRIMA has already restored functional vision in late‑stage macular degeneration patients, earning coverage in NEJM and on Time’s cover. The company has filed for CE‑mark approval in the EU and is pursuing FDA clearance, with a European launch slated for later this year.